Bone disease in patients with Gaucher disease
- 7 January 2014
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 9 (2) , 153-162
Abstract
Gaucher disease is an inborn error of metabolism due to a deficiency of the lysosomal enzyme glucocerebrosidase. As a result of this deficiency, the substrate glucocerebroside accumulates in the liver, spleen, bone and bone marrow. Bone involvement can lead to abnormalities in bone growth, bone remodeling, bone infarcts, aseptic necrosis, osteonecrosis, increased fracture risk and lytic bone lesions. Patients may experience bone pain and bone crises related to bone infarcts. There is evidence of abnormal bone metabolism in both bone resorption and bone formation based upon biochemical abnormalities found in patients. In addition, both immunological and coagulation abnormalities have in part been implicated in the causation of bone disease. Treatment with enzyme replacement therapy and substrate reduction therapy has led to improvement in both the symptoms and the radiographic abnormalities seen in these patients. It is unknown whether these treatments lower fracture risk.Keywords
This publication has 84 references indexed in Scilit:
- Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic reviewNutrition & Metabolism, 2013
- Long‐term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatmentJournal of Inherited Metabolic Disease, 2012
- Osteopenia in Gaucher disease develops early in life: Response to imiglucerase enzyme therapy in children, adolescents and adultsBlood Cells, Molecules, and Diseases, 2011
- Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophageProceedings of the National Academy of Sciences, 2010
- Osteonecrosis is not a predictor of poor outcomes in primary total hip arthroplasty: a systematic literature reviewInternational Orthopaedics, 2010
- Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosisBritish Journal of Haematology, 2009
- Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretomeBlood, 2009
- Characterization of gene-activated human acid- -glucosidase: Crystal structure, glycan composition, and internalization into macrophagesGlycobiology, 2009
- Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48‐month longitudinal cohort studyClinical Genetics, 2008
- Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher diseaseSkeletal Radiology, 2008